ReviewCurrent rheumatology reports2015
Giant cell arteritis and polymyalgia rheumatica: an update.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 72 citations in OpenAlex.
- Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.Arthritis research & therapy · 2019Trial
- Article
- Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.Journal of clinical medicine · 2024Review
- Positron Emission Tomography/Computed Tomography in Polymyalgia Rheumatica: When and for What-A Critical Review.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluation of the extracranial "multifocal arcuate sign," a novel MRI finding for the diagnosis of giant cell arteritis, on STIR and contrast-enhanced T1-weighted images.BMC medical imaging · 2024Article
- [Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2023Article
- The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides.Frontiers in endocrinology · 2022Review
- Paraneoplastic giant cell arteritis and prostate cancer: A case report of a not common association.Clinical case reports · 2021Article
- Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides.Current rheumatology reports · 2021Review
- Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.Therapeutic advances in musculoskeletal disease · 2021Article
- Biologic Therapies for Giant Cell Arteritis.Biologics : targets & therapy · 2021Review
- [Current patient care of giant cell arteritis in Rhineland-Palatinate].Zeitschrift fur Rheumatologie · 2019Article
- Giant cell arteritis: is the clinical spectrum of the disease changing?BMC geriatrics · 2019Review
- The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases.The Journal of rheumatology · 2018Article
- A Stab in the Dark: A Case Report of an Atypical Presentation of Giant Cell Arteritis (GCA).Geriatrics (Basel, Switzerland) · 2018Article
- Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.Seminars in arthritis and rheumatism · 2017Article
- Estimating the Cost of Illness of Giant Cell Arteritis in the United States.Rheumatology and therapy · 2017Article
- Gastrointestinal aspects of vasculitides.Nature reviews. Gastroenterology & hepatology · 2017Review
- The Treatment of Giant Cell Arteritis.Current treatment options in neurology · 2017Review
- Giant cell arteritis: ophthalmic manifestations of a systemic disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two closely related diseases in people aged 50 years and older, which are more frequently observed in Western countries. Despite being common entities, concern still exists about the epidemiology, pathogenesis, and diagnosis of both entities. New imaging techniques, such as 18 fluorodeoxyglucose-positron emission tomography, have proved to be useful in detecting large-vessel involvement in GCA. Corticosteroids are the cornerstone of the therapy in GCA and PMR. Relapses are frequent in these conditions. Unlike methotrexate and tumor necrosis factor-α antagonists, anti-interleukin-6 receptor therapy appears to be useful in patients with GCA and PMR who are refractory to corticosteroids. This review summarizes recent studies on GCA and PMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.